Immuneering Corp

Immuneering Corp is a clinical-stage biotechnology company focused on developing oncology therapies, with an emphasis on MAPK pathway cancers and biomarker-driven patient selection. The company uses proprietary bioinformatics and translational models to identify indications and subpopulations that may be more sensitive to its product candidates, while it remains pre-commercial with no approved products or sales infrastructure.

17.50

17.50

— Immuneering Corp
%
Oncology drug candidates0% Internally developed therapeutic candidates aimed at MAPK pathway-driven cancers and related tumors.
Bioinformatics platform0% Software and analytical methods used to interpret genomic and clinical data for target selection.
Translational research0% Preclinical and clinical analysis used to prioritize indications and identify sensitive subpopulations.
Future commercialization rights0% Potential direct commercialization or partnered regional commercialization of approved products.

Immuneering does not currently sell commercial products, so its near-term 'customers' are primarily regulators,...

  • Clinical investigators and trial sitesprimary

    They run the studies needed to generate safety and efficacy data for the company's oncology pipeline.

  • Regulatory authoritiesprimary

    FDA, EMA and other agencies determine whether product candidates can advance to approval and market entry.

  • Potential pharmaceutical partnerssecondary

    Partners may license or co-develop assets in select regions to help fund development and commercialization.

  • Oncology patients and treating physiciansprimary

    Future end users of approved therapies, especially in MAPK pathway cancers and biomarker-defined subgroups.

  • Third-party payorssecondary

    Insurers and health systems would buy coverage for approved therapies if reimbursement supports access.

Immuneering is headquartered in Cambridge, Massachusetts and is building a U.S.-first commercialization plan, with...

  • •Headquartered in Cambridge, Massachusetts, United States
  • •Primary development and future commercialization focus is the U.S.
  • •May pursue select ex-U.S. regions through partners if approved
  • •Clinical and regulatory activity may span the U.S. and Europe
  • •No current sales or commercial distribution infrastructure

The company’s strategy is to use its bioinformatics and translational capabilities to choose the most promising...

01
Advance MAPK-pathway oncology programsshort-term

Clinical proof-of-concept is required before any commercial value can be realized.

02
Improve indication selection and patient stratificationshort-term

Better targeting can increase response rates and improve trial efficiency.

03
Secure additional capital and non-dilutive fundingshort-term

The company expects to need more funding to continue development beyond its current cash runway.

04
Preserve commercialization optionalitymedium-term

Retaining rights in major markets could maximize long-term value if a candidate succeeds.

Immuneering is a pre-revenue clinical-stage oncology company, so its value depends on successful trials, regulatory...

critical

Clinical development failure

The company has no approved products and depends on successful trials to create value.

Scope
Pipeline-dependent oncology programs
Materiality
high
critical

Financing and going-concern risk

Recurring losses and limited cash require additional funding to continue operations.

Scope
Equity, debt, collaborations, licensing
Materiality
high
high

Commercialization and reimbursement risk

Even if approved, uptake depends on coverage, reimbursement, and pricing.

Scope
U.S. and international payor systems
Materiality
high
high

Competitive intensity in oncology

Larger biopharma firms and academic groups may develop safer or more effective therapies faster.

Scope
MAPK pathway and RAS/RAF mutant tumors
Materiality
medium
medium

Intellectual property risk

Future success depends on protecting proprietary platform and product rights.

Scope
Patent prosecution and defense
Materiality
medium
Pre-revenue operating model
Losses and cash burn are the key reported metrics
Clinical trial accruals
Quarterly expense volatility
Stock-based compensation
Affects operating loss and non-cash expense
Going-concern assessment
Signals liquidity risk and financing dependence

Mosaic ImmunoEngineering Inc.

CPMV · Biological Products, (No Diagnostic Substances)

Replimune Group, Inc.

REPL · Biological Products, (No Diagnostic Substances)

Compass Therapeutics, Inc.

CMPX · Biological Products, (No Diagnostic Substances)

Janux Therapeutics, Inc.

JANX · Pharmaceutical Preparations

GENELUX Corp

GNLX · Pharmaceutical Preparations

Greenwich LifeSciences, Inc.

GLSI · Pharmaceutical Preparations

: 28/04/2026